Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

January 4, 2024

Primary Completion Date

August 5, 2024

Study Completion Date

September 18, 2024

Conditions
Moderate to Severe Plaque Psoriasis
Interventions
DRUG

ICP-488 Tablets

ICP-488 will be administered as tablet

DRUG

ICP-488 Placebo

ICP-488 Placebo will be administered as tablet

Trial Locations (31)

100000

Beijing Friendship Hospital, Capital Medical University, Beijing

China-Japan Friendship Hospital, Beijing

130000

First Hospital of Jilin University, Changchun

135099

Mei he kou central hospital, Meihekou

200000

Shanghai Dermatology Hospital, Shanghai

200040

Huashan Hospital Affiliated to Fudan University, Shanghai

210042

Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of medical Sciences, Peking Union Medical College, Nanjing

213000

Changzhou First People's Hospital, Changzhou

222000

Lianyungang First People's Hospital, Lianyungang

250013

Central Hospital affiliated to shandong first medical unversity, Jinan

310000

Hangzhou First People's Hospital, Hangzhou

Zhejiang Provincial People's Hospital, Hangzhou

314000

The First Hospital of Jiaxing, Jiaxing

325000

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

350000

The First Affiliated Hospital of Fujian Medical University, Fuzhou

400000

The First Affiliated Hospital of Chongqing Medical University, Chongqing

410008

Xiangya hospital central south university, Changsha

430000

Wuhan University People's Hospital, Wuhan

430030

Wuhan No.1 hospital, Wuhan

442000

Shiyan City People's Hospital, Shiyan

450000

Henan Provincial People's Hospital, Zhengzhou

473000

Nanyang city first People's Hospital, Nanyang

510000

Dermatology Hospital of Southern Medical University, Guangzhou

510120

Guangdong Hospital of Traditional Chinese Medicine, Guangzhou

550081

Affiliated Hospital of Guizhou Medical University, Guiyang

610000

Chengdu Second People's Hospital, Chengdu

650000

The First Affiliated Hospital of Kunming Medical University, Kunming

067032

The Affiliated Hospital of Chengde Medical College, Chengde

050000

The first hospital of hebei medical university, Shijiazhuang

The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang

010000

Affiliated Hospital of Inner Mongolia Medical University, Hohhot

All Listed Sponsors
lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY

NCT06109818 - Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter